Hester Biosciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The Animal Division, which includes both Ruminants and Pet health products, reported an 8% growth in revenue to Rs 30.53 crore in Q4 FY25.

The Poultry Healthcare division?s revenue grew by 3% YoY to Rs 46.08 crore during the period under review.

While EBITDA expanded by 8% YoY to Rs 14.76 crore, EBITDA margin remained constant at 19%.

On a consolidated basis, the company has recorded 76% drop in net profit to Rs 1.54 crore even as a revenues increased by 3% to Rs 81.92 crore in Q4 FY25 over Q4 FY24.

For FY25, Hester Bio has registered a net profit of Rs 28.82 crore (up 36% YoY) and revenue from operations of Rs 304.54 crore (up 2% YoY).

In its outlook, the company said that it remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities.

In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth.

Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare,? the company stated.

Hester Biosciences Limited is one of the India?s leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

The scrip slipped 3.20% to currently trade at Rs 1643.50 on the BSE.

Powered by Capital Market - Live News

Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024.

For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024.

For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 9 May 2025.

Powered by Capital Market - Live News

The Animal Division, which includes both Ruminants and Pet health products, reported an 8% growth in revenue to Rs 30.53 crore in Q4 FY25.

The Poultry Healthcare division?s revenue grew by 3% YoY to Rs 46.08 crore during the period under review.

While EBITDA expanded by 8% YoY to Rs 14.76 crore, EBITDA margin remained constant at 19%.

On a consolidated basis, the company has recorded 76% drop in net profit to Rs 1.54 crore even as a revenues increased by 3% to Rs 81.92 crore in Q4 FY25 over Q4 FY24.

For FY25, Hester Bio has registered a net profit of Rs 28.82 crore (up 36% YoY) and revenue from operations of Rs 304.54 crore (up 2% YoY).

In its outlook, the company said that it remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities.

In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth.

Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare,? the company stated.

Hester Biosciences Limited is one of the India?s leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

The scrip slipped 3.20% to currently trade at Rs 1643.50 on the BSE.

Powered by Capital Market - Live News

Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024.

For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024.

For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 9 May 2025.

Powered by Capital Market - Live News